Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials

Eric Lawitz, Maria Buti, John M. Vierling, Piero L. Almasio, Savino Bruno, Peter J. Ruane, Tarek I. Hassanein, Beat Muellhaupt, Brian Pearlman, Ligita Jancoriene, Wei Gao, Hsueh Cheng Huang, Aimee Shepherd, Brynne Tannenbaum, Doreen Fernsler, Jerry J. Li, Anjana Grandhi, Hong Liu, Feng Hsiu Su, Shuyan WanFrank J. Dutko, Bach Yen T. Nguyen, Janice Wahl, Michael N. Robertson, Eliav Barr, Wendy W. Yeh, Rebeca M. Plank, Joan R. Butterton, Eric M. Yoshida

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials'. Together they form a unique fingerprint.

Medicine & Life Sciences